(Total Views: 499)
Posted On: 11/05/2019 1:14:21 AM
Post# of 153903
525mg was at 75% and 700mg was at 82% in June. Huge jump from 350mg.
https://content.equisolve.net/_0fabb8b784fee9..._Final.pdf
Also, 525mg was at 90% after 10 weeks before the overlap was added and has been trending upward after the overlap. So the numbers with the new overlap will be higher. And these results have the dose assigned randomly, with the density test, they will assign 350mg only the ones that have low density, which from the previous publication on the phase 2 trial stated the density was 60% higher on average in the failure group.
Look at this post for who I think will be given 350mg.
https://m.investorshangout.com/post/view?id=5565423
https://content.equisolve.net/_0fabb8b784fee9..._Final.pdf
Also, 525mg was at 90% after 10 weeks before the overlap was added and has been trending upward after the overlap. So the numbers with the new overlap will be higher. And these results have the dose assigned randomly, with the density test, they will assign 350mg only the ones that have low density, which from the previous publication on the phase 2 trial stated the density was 60% higher on average in the failure group.
Look at this post for who I think will be given 350mg.
https://m.investorshangout.com/post/view?id=5565423
(0)
(0)
